<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210220050419N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-27</date_registration>
      <primary_sponsor>Research Institute of Ophthalmology</primary_sponsor>
      <public_title>Ketamine versus magnesium sulphate as an adjuvant to local anesthetics in the peribulbar block for posterior segment surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Ketamine versus magnesium sulphate as an adjuvant to local anesthetics in the peribulbar block for posterior segment surgeries: A randomized controlled study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-04-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54441</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: We used the sealed, opaque sequentially numbered envelopes method for randomization and allocation concealment of patients included in this trial. We used 126 identical, opaque, letter-sized envelopes lined with sheets of household aluminum cooking foil to ensure opacity. We prepared 126 envelope-sized sheets of white paper and 126 envelope-sized sheets of single sided carbon paper. We wrote “Treatment A” on 42 paper sheets, “Treatment B” on another 42 sheets, and “Treatment C” on the last 42 sheets. To prepare 42 “Treatment A” envelops, we selected one envelope-sized sheet of Treatment A and placed one sheet of carbon paper on top of the Treatment A allocation paper with the carbon side facing the paper, then we inserted both into a blank envelope with the carbon paper closest to the front of the envelope. Finally, we sealed the envelop and signed across the seal. We completed all the 42 “Treatment A” envelops the same way. We prepared 42 “Treatment B” as well as 42 “Treatment C” envelops similar to “Treatment A” envelops. The three sets of envelops were combined and shuffled thoroughly. Using a pen, we marked a number on the front of each envelope sequentially from 1 to 126 so the carbon paper inside the envelope transfer this number to the allocation paper inside. Finally, we placed these envelopes into a large plastic container, in numerical order, ready for use, Blinding description: The study participants and care providers (carrying out the peribulbar block and assessing the participants' outcomes) were blinded to the type of intervention.</study_design>
      <phase>2</phase>
      <hc_freetext>Peribulbar block in adult patients undergoing posterior segment surgeries..</hc_freetext>
      <i_freetext>Intervention 1: Control group (GC) received peribulbar anesthesia with a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture). Intervention 2: Intervention group (GK) received a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 25 mg of ketamine in 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture). Intervention 3: Intervention group (GM) received a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 50 mg of magnesium sulphate in 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Ketamine and magnesium sulphate in peribulbar block for posterior segment surgeries IPD set (all collected deidentified IPD).

When:
Beginning 6 months and ending 24 months following article publication.

To whom:
Researchers from academic institutions whose proposal for the use of data has been approved by an independent review committee identified for this purpose.

Conditions:
For IPD meta-analyses.

Where to obtain:
From the principal investigator (A proposal for the use of data to be submitted to the principal investigator).

How to obtain:
proposal for the use of data to be submitted to the principal investigator, then evaluated by an independent review committee identified for this purpose.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Eslam Saleh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2 El Ahram Street</address>
        <city>Giza</city>
        <country1>Egypt</country1>
        <zip>31527</zip>
        <telephone>+20 2 35718304</telephone>
        <email>dr.eslam.m.saleh@gmial.com</email>
        <affiliation>Research Institute of Ophthalmology</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Eslam Saleh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2 El Ahram Street</address>
        <city>Giza</city>
        <country1>Egypt</country1>
        <zip>31527</zip>
        <telephone>+20 2 35718304</telephone>
        <email>dr.eslam.m.saleh@gmial.com</email>
        <affiliation>Research Institute of Ophthalmology</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Egypt</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Posterior segment operations
American Society of Anesthesiologist (ASA) physical status I or II
Age: 45-65 years
Axial length: &lt; 25 mm</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Coagulation abnormalities
Impaired mental status
Allergy to any of the study medications
Problems that interfere with surgeon patient communication and cooperation as deafness
Severe cardiac disease, chronic obstructive lung disease, history of sleep apnea, advanced liver or kidney disease
History of chronic use of sedatives, narcotics, alcohol or drug abuse
Patient refusal</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group (GC) received peribulbar anesthesia with a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture).</i_keyword>
      <i_keyword>Intervention group (GK) received a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 25 mg of ketamine in 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture).</i_keyword>
      <i_keyword>Intervention group (GM) received a local anesthetic mixture composed of lidocaine 2% (4.5 ml), plain bupivacaine 0.5% (4.5 ml), 50 mg of magnesium sulphate in 1 ml of normal saline, and hyaluronidase (13.5 IU per ml of the local anesthetic mixture).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The onset of sensory block. Timepoint: At 1, 2, 3, 4, and 5 min after the block. Method of measurement: A small piece of cotton wool.</prim_outcome>
      <prim_outcome>The onset of globe akinesia. Timepoint: At 1, 3, 5, 7, and 10 min after the block. Method of measurement: The 3-point scale.</prim_outcome>
      <prim_outcome>The Duration of lid akinesia. Timepoint: At 1, 2, 3, 4, and 5 h postoperative. Method of measurement: Clinical assessment of regaining full movement.</prim_outcome>
      <prim_outcome>The duration of globe akinesia. Timepoint: At 1, 2, 3, 4, and 5 h postoperative. Method of measurement: Clinical assessment of regaining full movement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: After recovery. Method of measurement: 7-point Likert-like verbal rating scale.</sec_outcome>
      <sec_outcome>Surgeon satisfaction. Timepoint: At the end of surgery. Method of measurement: The 7-point Likert-like verbal rating scale.</sec_outcome>
      <sec_outcome>The duration of analgesia. Timepoint: At 1, 2, 3, 4, and 5 h postoperative. Method of measurement: The 10-point Visual Analog Scale.</sec_outcome>
      <sec_outcome>The intraocular pressure. Timepoint: At baseline and 10 minutes after injection of the local anesthetics. Method of measurement: Schiotz tonometer.</sec_outcome>
      <sec_outcome>Time to start surgery. Timepoint: At 1, 3, 5, 7, and 10 min after the block. Method of measurement: Corneal anesthesia together with an ocular movement score ≤1 in each direction and an eyelid akinesia score of 0 (total score &lt;5).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-funded</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-11</approval_date>
        <contact_name>Research Ethical Committee of the Research Institute of Ophthalmology</contact_name>
        <contact_address>2 El Ahram Street Giza Cairo Egypt</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
